Bank of New York Mellon Corp Has $497,000 Stock Position in Fresenius Medical Care AG (NYSE:FMS)

Bank of New York Mellon Corp increased its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 5.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,951 shares of the company’s stock after purchasing an additional 1,205 shares during the quarter. Bank of New York Mellon Corp’s holdings in Fresenius Medical Care were worth $497,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the company. ABC Arbitrage SA bought a new stake in Fresenius Medical Care during the fourth quarter worth approximately $4,215,000. Quantinno Capital Management LP grew its holdings in shares of Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares during the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Fresenius Medical Care during the fourth quarter valued at approximately $983,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Fresenius Medical Care in the third quarter valued at about $420,000. Finally, XTX Topco Ltd boosted its stake in Fresenius Medical Care by 70.8% in the third quarter. XTX Topco Ltd now owns 39,769 shares of the company’s stock valued at $847,000 after acquiring an additional 16,487 shares during the last quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on FMS. Truist Financial lifted their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd.

Fresenius Medical Care Stock Performance

Shares of FMS stock opened at $24.58 on Friday. The stock has a market capitalization of $14.42 billion, a PE ratio of 20.31, a PEG ratio of 0.76 and a beta of 0.99. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $25.25. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The business’s 50 day simple moving average is $23.99 and its 200 day simple moving average is $22.48.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.